Full-Time

Principal Engineer

Confirmed live in the last 24 hours

Amgen

Amgen

10,001+ employees

Develops biologic therapies for serious illnesses

Compensation Overview

$147k - $178k/yr

+ Bonus + Stock-based long-term incentives

Senior, Expert

Holly Springs, NC, USA

Category
Backend Engineering
Software Engineering
Requirements
  • High School Diploma/GED and 12 years of direct experience in Engineering or a related technical field OR
  • Associate's degree and 10 years of direct experience in Engineering or a related technical field OR
  • Bachelor’s degree and 6 years of direct experience in Engineering or a related technical field OR
  • Master’s degree and 4 years of direct experience in Engineering or a related technical field OR
  • Doctorate degree and 2 years of direct experience in Engineering or a related technical field
Responsibilities
  • Translate business needs into engineering technology and design solutions.
  • Lead analysis of alternatives and recommendations for technical solutions in major projects.
  • Lead Engineering in development and implementation of corporate initiatives, goals & projects.
  • Lead design and equipment selection of process equipment, utilities, laboratory and building systems to optimize quality and cost across the total life cycle of assets.
  • Ensure appropriate use of technology, and alignment to standards/practices.
  • Approve appropriate exceptions to Amgen standards and specifications.
  • Provide engineering support during construction, resolve technical issues, and ensure project objectives are met.
  • Ensure commissioning standards are developed and implemented during system qualification.
  • Assist sites in troubleshooting, and remediation to prevent future occurrence throughout the network.
  • Support the implementation of sustainable and digital solutions to advance performance.
Desired Qualifications
  • Extensive experience with Drug Substance manufacturing equipment design and delivery.
  • Extensive experience in the delivery of capital projects as part of the design team.
  • Ability to provide direction and guidance to equipment vendors to deliver for the capital projects.
  • Experience in providing technical support to manufacturing facilities.
  • Track record of compliance in a highly regulated environment.
  • Ability to optimally lead and partner in matrixed organizations.
  • Successful deployment of continuous improvement methodologies (e.g., Lean, Six Sigma, Total Quality Management, Reliability Centered Maintenance, Root Cause Analysis tools, etc.).
  • Demonstrated experience in selection of and implementation of design elements for improved sustainability.

Amgen develops medicines aimed at treating serious illnesses, focusing on biotechnology. The company researches, develops, and sells biologic therapies, which are medicines made from living organisms. These therapies target conditions like cancer, cardiovascular diseases, and autoimmune disorders. Amgen stands out from competitors by reinvesting a large portion of its earnings into research and development, ensuring a strong pipeline of new treatments. The goal of Amgen is to improve patient care and address critical health challenges through its innovative therapeutic solutions.

Company Size

10,001+

Company Stage

IPO

Headquarters

Thousand Oaks, California

Founded

1980

Simplify Jobs

Simplify's Take

What believers are saying

  • Amgen's investment in AI aligns with trends in biotechnology innovation.
  • Institutional investments indicate strong market confidence in Amgen's growth.
  • FTC clearance of the Horizon merger may ease future regulatory hurdles.

What critics are saying

  • Competitors' AI-driven drug discovery could outpace Amgen's traditional R&D methods.
  • FTC scrutiny of mergers may complicate Amgen's future growth strategy.
  • Advancements in quantum technologies could pose a competitive threat to Amgen.

What makes Amgen unique

  • Amgen focuses on biologic therapies derived from living organisms.
  • The company has a strong pipeline of potential new therapies in development.
  • Amgen's acquisition of Horizon Therapeutics enhances its rare disease portfolio.

Help us improve and share your feedback! Did you find this helpful?

Benefits

Professional Development Budget

Conference Attendance Budget

Company News

MarketBeat
Jan 28th, 2024
Factory Mutual Insurance Co. Makes New Investment in Amgen Inc. (NASDAQ:AMGN)

Factory Mutual Insurance Co. purchased a new position in Amgen Inc. (NASDAQ:AMGN - Free Report) during the 3rd quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The firm purchased 53,500 shares of the medical research company's stock, valued at approxim

The Quantum Insider
Jan 16th, 2024
Honeywell Announces the Closing of $300 Million Equity Investment Round for Quantinuum at $5 Billion Pre-Money Valuation

JPMorgan Chase has one of the world's most highly regarded specialist teams working on quantum technologies within the financial services industry and has been working with Quantinuum and its predecessor companies since 2020.

ETF Daily News
Dec 17th, 2023
Northwest Quadrant Wealth Management LLC Invests $237,000 in Amgen Inc. (NASDAQ:AMGN)

Northwest Quadrant Wealth Management LLC bought a new position in shares of Amgen Inc. (NASDAQ:AMGN – Free Report) during the third quarter, according to its most recent disclosure with the Securities & Exchange Commission. The fund bought 883 shares of the medical research company’s stock, valued at approximately $237,000. A number of other institutional investors […]

Horizon Therapeutics
Sep 21st, 2023
Rule 2.7 Announcement: Amgen Inc to Acquire Horizon Therapeutics plc | Horizon Therapeutics plc

The Investor Relations website contains information about Horizon Therapeutics plc's business for stockholders, potential investors, and financial analysts.

BioSpace
Sep 19th, 2023
Amgen-Horizon Merger Clearance a Setback to FTC’s Antitrust Enforcement Plans

The consent agreement struck between the FTC and Amgen and Horizon Therapeutics could have significant implications for ongoing and future M&A challenges, experts told BioSpace.